Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine

  • Home
  • 2022
  • April
  • 27
  • Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine

Original Source

On April 27, 2022

Post navigation

Previous PostEntergy reports first quarter earnings
Next PostIQVIA Reports First-Quarter 2022 Results

Related Post

May 21, 2022
  • Business News

Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol

May 20, 2022
  • Business News

Boeing’s Starliner Spacecraft Completes Successful Docking to Space Station

May 20, 2022
  • Business News

Entergy’s Palisades team finishes strong as facility shuts down

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219